XTalks

MAY 23, 2024

Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. In fact, tools such as dermatoscopes, digital imaging systems and artificial intelligence (AI)-powered diagnostic tools have become integral to dermatological practice.

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

XTalks

JANUARY 2, 2024

a biotech company specializing in the development and commercialization of genetic medicines for rare diseases, announced FDA approval for Vyjuvek for the treatment of DEB. Upon Vyjuvek’s entry into cells, the vector genome is integrated into the nucleus, initiating the transcription of the encoded human COL7A1.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

The Pharma Data

JUNE 19, 2022

A new study led by Penn State College of Medicine scientists finds that another type of immune cell – natural killer cells – can be harnessed to pick up the slack when T cells no longer work and may also reinvigorate T cells to attack melanoma tumors.

Drugs 52

Drugs Protein Immune Response Dermatology 52

Drug Discovery World

APRIL 15, 2024

Absci has been working within this space for a while, having recently signed deals with AstraZeneca and Almirall to discover and develop targets within oncology and dermatology, using its generative AI platform and wet lab capabilities. There are initiatives out there that are aimed at enabling greater access to data.

Antibody 59

Antibody Drugs In-Vivo Life Science 59

The Pharma Data

JULY 23, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. endocrinopathies and dermatologic reactions) are discussed below.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

MARCH 11, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. endocrinopathies and dermatologic reactions) are discussed below.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

JANUARY 6, 2021

Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the public of $29.50 7, 2021 05:00 UTC. LA JOLLA, Calif.–(

Dermatology 40

Dermatology Genome Genomics Production 40